Daiichi Sankyo Company, Limited (DSNKY)
OTCMKTS
· Delayed Price · Currency is USD
23.49
+0.15 (0.64%)
Apr 24, 2025, 12:40 PM EDT
Daiichi Sankyo Company Revenue
Daiichi Sankyo Company had revenue of 484.84B JPY in the quarter ending December 31, 2024, with 8.48% growth. This brings the company's revenue in the last twelve months to 1.80T, up 19.46% year-over-year. In the fiscal year ending March 31, 2024, Daiichi Sankyo Company had annual revenue of 1.60T with 25.28% growth.
Revenue (ttm)
1,795.99B JPY
Revenue Growth
+19.46%
P/S Ratio
3.80
Revenue / Employee
95.91M JPY
Employees
18,726
Market Cap
43.42B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 1,601.69B | 323.21B | 25.28% |
Mar 31, 2023 | 1,278.48B | 233.59B | 22.36% |
Mar 31, 2022 | 1,044.89B | 82.38B | 8.56% |
Mar 31, 2021 | 962.52B | -19.28B | -1.96% |
Mar 31, 2020 | 981.79B | 52.08B | 5.60% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SS Innovations International | 20.65M |
Endo Inc. | 1.76B |
Veradigm | 588.02M |
Northwest Biotherapeutics | 1.38M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 200.90M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
Daiichi Sankyo Company News
- 3 days ago - ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer - Benzinga
- 12 days ago - Daiichi Sankyo: Good Diversification Tool For U.S. Investors - Seeking Alpha
- 16 days ago - Daiichi Sankyo and AstraZeneca get EU approval for Datroway - Seeking Alpha
- 19 days ago - European Drug Regulator Approves AstraZeneca's Two Flagship Cancer Drugs For Breast And Lung Cancer Settings - Benzinga
- 24 days ago - DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer - Benzinga
- 4 weeks ago - Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed - Benzinga
- 6 weeks ago - Nosis Biosciences Announces Research Collaboration and Option Agreement with Daiichi Sankyo to Develop Cell-Targeted RNA Medicines - Business Wire
- 7 weeks ago - Daiichi Sankyo and AstraZeneca report positive result in trial for its gastric cancer treatment - Seeking Alpha